We report on two cases of patients with <i>TSC</i>-mutated sarcomas who experienced significant responses to the combination of gemcitabine and sirolimus, after progression on prior gemcitabine-based chemotherapy and single agent mTOR inhibition with <i>nab</i>-sirolimus. This evidence concerns the gene MTOR and sarcoma.